TLR7 and neoplasm: There is alreadyan FDA-approved TLR7/8 agonist, imiquimod, which is applied topicallyfor superficial basal cell carcinoma.57 A variety of drug delivery strategies are under investigation toincrease the therapeutic efficacy of these agonists.17,58 Our PDS-mediated tumor cell-surface-binding and tumor retentionplatform could further improve the therapeutic efficacy and/or toxicityprofile of such therapeutics.